Abstract
Oxaliplatin, a third-generation platinum agent, has been used for the treatment of colon, pancreatic, and stomach cancers in recent years. It carries a reduced risk of acute kidney injury (AKI) compared to the previous platinum agents, including cisplatin and carboplatin. Several cases of oxaliplatin-induced acute tubular necrosis (ATN) have been reported; however, only one case has been reported as acute tubulointerstitial nephritis (ATIN) histopathologically. Here, we present a case of biopsy-proven and dialysis-dependent ATIN, which dramatically resolved with steroid therapy. The patient was a 67-year-old male who had undergone chemotherapy for colon adenocarcinoma. He suddenly developed shaking chills, fever, and hot flashes at the end of the 18th 5-fluorouracil (5-FU)/l-leucovorin/oxaliplatin administration, and was admitted to our hospital. On the 4th day of hospitalization, severe renal dysfunction (creatinine 6.5 mg/dL) was observed. As oliguria continued, we initiated hemodialysis therapy on the 6th day of hospitalization. Drug-induced ATIN was strongly suspected due to the history of multiple exposures to oxaliplatin with allergic reaction and sterile pyuria. We began steroid therapy on the 8th day of hospitalization. Subsequently, renal biopsy was performed and the diagnosis of ATIN was made. The patient’s renal function gradually improved, and 6 months later, it had returned to baseline. Our case demonstrates that we should consider not only ATN, but also ATIN, as potential presentations of oxaliplatin-induced AKI.
Similar content being viewed by others
References
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.
Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141–5.
Polyzos A, Tsavaris N, Gogas H, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology. 2009;76:36–41.
Pinotti G, Martinelli B. A case of acute tubular necrosis due to oxaliplatin. Ann Oncol. 2002;13:1951–2.
Phan NT, Heng AE, Lautrette A, et al. Oxaliplatin-induced acute renal failure presenting clinically as thrombotic micro-angiopathy: think of acute tubular necrosis. NDT Plus. 2009;2:254–6.
Filewod N, Lipman ML. Severe acute tubular necrosis observed subsequent to oxaliplatin administration. Clin Kidney J. 2014;7:68–70.
Labaye J, Sarret D, Duvic C, et al. Renal toxicity of oxaliplatin. Nephrol Dial Transplant. 2005;20:1275–6.
Joybari AY, Sarbaz S, Azadeh S, et al. Oxaliplatin-induced renal tubular vacuolization. Ann Pharmacother. 2014;48:796–800.
Ashrafi F, Nematbakhsh M, Nasri H, Talebi A, Hosseini SM, Ashrafi M. Vacuolization, dilatation, hyaline cast, debris or degeneration: which one is the most correlated item to score the kidney damage pathologically in cisplatin induced nephrotoxicity model? Nephrourol Mon. 2014;5:918–20.
Yonezawa A, Masuda S, Yokoo S. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319:879–86.
Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol. 2007;74:477–87.
Yonezawa A, Inui KI. Organic cation transporter OCT/SLC22A and H+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol. 2011;81:563–8.
Ito I, Ito Y, Mizuno M, et al. A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin. Clin Exp Nephrol. 2012;16:490–4.
Muriithi AK, Nasr SH, Leung N. Utility of urine eosinophils in the diagnosis of acute interstitial nephritis. Clin J Am Soc Nephrol. 2013;8:1857–62.
Koselj M, Kveder R, Bren AF, et al. Acute renal failure in patients with drug-induced acute interstitial nephritis. Ren Fail. 1993;15:69–72.
Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809–20.
Perazella MA. Diagnosing drug-induced AIN in the hospitalized patient: a challenge for the clinician. Clin Nephrol. 2014;81(6):381–8.
Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in 2015—from epidemiology to evidence-based indications. Am J Nephrol. 2016;43:1–19.
Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77:956–61.
Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis 1993–2011: a case series. Am J Kidney Dis. 2014;64:558–66.
Pierce A, Nester T. Pathology consultation on drug-induced hemolytic anemia. Am J Clin Pathol. 2011;136:7–12.
Acknowledgements
We would like to thank Editage (http://www.editage.jp) for English language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to declare.
Human and animal rights
This article does not contain any studies with human participants performed by any of the authors.
Informed consent
Informed consent was obtained from the patient described in the study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yamada, S., Yazawa, M., Yamamoto, M. et al. A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia. CEN Case Rep 8, 188–193 (2019). https://doi.org/10.1007/s13730-019-00390-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-019-00390-8